

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (HI-98) ANSUVIMAB
 PRONUNCIATION an soo' vi mab
 THERAPEUTIC CLAIM Treatment of *Ebola* virus

CHEMICAL NAMES

1. Immunoglobulin G1, anti-(Zaire ebolavirus glycoprotein glycan cap and GP1 domain) (human monoclonal mAb114 γ 1-chain), disulfide with human monoclonal mAb114 κ -chain, dimer
2. Immunoglobulin G1-kappa, anti-(*Zaire ebolavirus* Envelope glycoprotein GP1 subunit glycan cap domain(subunit (III))); human monoclonal antibody; γ 1 heavy chain (1-449) [*Homo sapiens* VH (IGHV3-13*01 (78%) –(IGHD)-IGHJ5*01 (93%)) [8.7.13] (1-119) -*Homo sapiens* IGHG1*01 (120-449)], (222-214')-disulfide with κ light chain (1'-214') [*Homo sapiens* V-KAPPA (*Homo sapiens* IGKV1-27*01 (87%) –IGKJ4*01)[6.3.9] (1'-108') -*Homo sapiens* IGKC*01 (109'-214')], dimer (228-228":231-231")-bisdisulfide

STRUCTURAL FORMULA

Heavy chain

EVQLVESGGG	LIQPGGSLRL	SCAASGFALR	MYDMHWVRQT	IDKRLEWVSA	50
VGPSGDTTYA	DSVKGRFAVS	RENAKNSLSL	QMNSLTAGDT	AIYYCVRSRDR	100
GVAGLFDSWG	QGILVTVSSA	STKGPVVFPL	APSSKSTSGG	TAALGCLVKD	150
YFPEPVTVSW	NSGALTSGVH	TFFPAVLQSSG	LYSLSSVTV	PSSSLGTQTY	200
ICNVNHNKPSN	TKVDKKVEPK	SCDKTHTCPP	CPAPELLGGP	SVFLFPPKPK	250
DTLMISRTPE	VTCVVDVSH	EDPEVKFNWY	VDGVEVHNAK	TKPREEQVNS	300
TYRVVSVLTV	LHQDWLNGKE	YKCKVSNKAL	PAPIEKTISK	AKGQPREPQV	350
YTLPPSRDEL	TKNQVSLTCL	VKGFYPSDIA	VEWESNGQPE	NNYKTTTPVL	400
DSDGSFFLYS	KLTVDKSRWQ	QGNVFSCSVM	HEALHNHYTQ	KSLSLSPGK	449

Light chain

DIQMTQSPSS	LSASVGDRIT	ITCRASQAFD	NYVAWYQQRP	GKVPKLLISA	50'
ASALHAGVPS	RFSGSGSGTH	FTLTISSLQP	EDVATYYCQN	YNSAPLTFGG	100'
GTKVEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV	150'
DNALQSGNSQ	ESVTEQDSKD	STYSLSSTLT	LSKADYEKHK	VYACEVTHQG	200'
LSSPVTKSFN	RGEC				214'

Disulfide bridges location

22-95	22"-95"	23'-88'	23'''-88'''	134'-194'	134'''-194'''	146-202	146"-202"
214'-222	214'''-222'''	228-228"	231-231"	263-323	263"-323"	369-427	369"-427"

Glycosylation sites (N)

Asn-299 Asn-299'

MOLECULAR FORMULA C₆₃₆₈H₉₉₂₄N₁₇₂₄O₁₉₉₄S₄₄ . (non-glycosylated)
 MOLECULAR WEIGHT 143.95 kDa (non-glycosylated)
 TRADEMARK None as yet
 SPONSOR Ridgeback Biopharmaceuticals

CODE DESIGNATIONS	MAB114, mAb114, VRC-EBOMAB092-00-AB, EboV mAb114
<u>CAS</u> REGISTRY NUMBER	2375952-29-5
UNII	TG8IQ19NG2
WHO NUMBER	11568

gbk